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Abstract
Background: Second-line treatment of advanced non-small-cell lung cancer (NSCLC) improves overall survival.
There is a lack of data regarding the impact on patients’ overall health condition. This prospective, non-
interventional study evaluated performance status (PS) and health-related quality of life (HR-QoL) during second-
line pemetrexed treatment in routine clinical practice.
Methods: Stage III/IV NSCLC patients who initiated second-line pemetrexed (standard vitamin and dexamethasone
supplementation) were observed for a maximum of 9 treatment cycles. The primary objective was to evaluate the
proportion of patients achieving improvement of Karnofsky Index (KI) of ≥ 10% (absolute) or maintaining KI ≥ 80%
after the second treatment cycle ("KI benefit response”). HR-QoL was self-rated using the EuroQoL-5D questionnaire
(EQ-5D). Factors potentially associated with KI benefit response were evaluated using logistic regression models.
Results: Of 521 eligible patients (73.5% Stage IV, median age 66.3 yrs, 36.1% ≥ 70 yrs, 62.0% with KI ≥ 80%), 471
(90.4%) completed at least 2 treatment cycles. 58.0% (95%CI 53.6%;62.2%) achieved KI benefit response after the
second cycle. Patients with baseline KI ≥ 80%, no Grade 3/4 toxicities during the first 2 cycles, or combination
regimen as prior first-line therapy were more likely to achieve a KI benefit response. EQ-5D scores improved over
time. Grade 3/4 toxicities were reported in 23.8% of patients (mainly fatigue/asthenia 15.9%, neutropenia 8.7%).
Conclusions: In this large prospective, non-interventional study of second-line pemetrexed treatment in patients
with advanced NSCLC, including 36% elderly patients ( ≥ 70 years), physician-rated PS and self-rated HR-QoL were
maintained or improved in the majority of patients.
Trial registration: Registered on ClinicalTrials.gov (NCT00540241) on October 4, 2007
Background
Second-line treatment of advanced non-small-cell lung
cancer (NSCLC) improves overall survival (OS),
although the survival benefit is still limited (6-8 months)
[1-4]. Because the most important purpose of second-
line treatment is palliation, maintenance or improve-
ment of a patient’s overall health condition is a highly
relevant treatment benefit. However, there is a lack of
prospective data regarding the impact of second-line
treatment on a patient’s overall health condition [5].
Patients’ overall health condition can be evaluated by
looking at their performance status (PS) as rated by a
physician, and/or by looking at health-related quality of
life (HR-QoL) as rated by the patient themselves. While
several clinical studies have shown that patient-rated
HR-QoL improves during second-line NSCLC treatment
[2,6,7], no study has specifically looked at changes in
physician-rated PS. In addition, the few studies that
have compared patient-and physician-rated outcomes
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patients themselves [8-11].
We designed a prospective, non-interventional multi-
center study in patients whose disease had progressed
after first-line chemotherapy for Stage III/IV NSCLC
and who were about to start second-line treatment with
pemetrexed, to evaluate physician-rated PS and patient-
rated HR-QoL during second-line treatment in routine
clinical practice. Due to the observational nature of this
study, we expected the patient population to be less
selected, including a significant proportion of patients
with poor PS, as well as elderly patients. For these popu-
lations, there is a particular lack of prospective data on
tumor response, survival and HR-QoL [12,13]. Elderly
patients are of special interest; they are rarely enrolled
into clinical trials, but more than two thirds of NSCLC
cases are diagnosed in patients aged ≥ 65 years [13].
The primary objective of this study was to evaluate the
proportion of patients who achieved an improvement of
Karnofsky Index (KI) or maintained a KI ≥ 80% after
the second cycle of pemetrexed treatment ("KI benefit
response”).
Methods
Patient population
Adult patients with NSCLC Stage IIIa/b or IV who were
about to start second-line treatment with single-agent
pemetrexed at the physician’s discretion were eligible to
participate in this non-interventional study. NSCLC sta-
ging was based on the fifth edition of the TNM classifi-
cation [14] because the study began in 2007.
Pemetrexed has been approved in the USA and Eur-
ope for the treatment of patients with advanced NSCLC
in the second-line setting since 2004. In 2008, new
pemetrexed first-line data revealed that patients with
predominantly non-squamous histology have a particu-
lar survival benefit [15,16]. Accordingly, the second-line
indication for pemetrexed was revised to include
patients with advanced NSCLC of predominantly non-
squamous histology only. Because our study began in
2007, i.e. before the label change, patients with both
squamous and non-squamous histology participated in
the study.
Patients were eligible if they had already received one
previous cytotoxic chemotherapy regimen; combination
with a targeted agent like erlotinib was allowed. How-
ever, patients who initially received a targeted agent
only and later received cytotoxic chemotherapy were
not eligible, because the initial targeted agent treatment
would have been regarded as first-line treatment. Pre-
vious pemetrexed treatment was not allowed. Physicians
routinely involved in the treatment of NSCLC were
asked to participate in the study. In- and outpatients
were enrolled at 102 hospitals and practices in Germany
(100 sites) and Austria (3 sites) between 09/2007 and
08/2009. All patients provided authorization for the use
and disclosure of their data collected during this non-
interventional study. The study protocol was reviewed
by ethical review boards in Germany and Austria (Ethics
Committee of the Landesärztekammer Hessen, Frank-
furt, Germany; Ethics Committee of the Country of
Oberösterreich, Linz, Austria).
Study design
This prospective, non-interventional phase IV multicen-
ter study (NCT00540241; H3E-SB-B007) evaluated
changes in physician-rated PS and patient-rated HR-
QoL during second-line treatment with pemetrexed in
routine clinical practice. The primary objective was to
evaluate the proportion of patients who achieved either
an improvement of KI of at least 10% (absolute) or
maintained a high KI of at least 80% ("KI benefit
response”) after the second cycle of second-line peme-
trexed treatment, and to identify factors which may be
associated with a benefit in KI. The KI benefit response
was primarily assessed after the second cycle because
physicians routinely evaluate patients’ clinical and func-
tional status thoroughly after the second treatment
cycle, and most patients can be expected to still be on
treatment. Secondary outcomes included patient-rated
HR-QoL (European Quality Of Life Five Dimensions
questionnaire [EQ-5D]), reasons for treatment disconti-
nuation, evaluation of prior chemotherapy, OS, physi-
cian-rated disease control, solicited toxicities, weight
loss, and use of solicited disease- or treatment-related
concomitant medications.
Treatment
It was assumed that physicians would administer peme-
trexed in accordance with the indication for second-line
treatment, as outlined in the current Summary of Pro-
duct Characteristics (SPC) for the respective countries.
According to the SPC, pemetrexed was to be adminis-
tered every 21 days (1 treatment cycle) at a dose of 500
mg/m
2, using standard vitamin supplementation and
dexamethasone prophylaxis. Any use of further conco-
mitant medication was at the physician’s discretion. The
duration of pemetrexed treatment was also at the discre-
tion of the physician. In clinical studies, second-line
pemetrexed treatment is commonly given over a median
of 4 cycles, with few patients exceeding 6 cycles [6]. In
this non-interventional study, patients were observed for
a maximum of 9 treatment cycles (treatment continued
at physician discretion).
Assessments
The baseline visit was to be scheduled approximately 1
week before administration of the first dose of
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day 1 of each treatment cycle, up to the last dose of
pemetrexed, but no longer than a maximum of 9 visits.
Final data were collected approximately 21 days after
the last recorded dose of pemetrexed. Following the last
patient visit, all participating physicians were contacted
once to collect final follow-up information on patient
survival.
Physician-rated KI [17], dose and administration of
pemetrexed, body weight, solicited relevant concomitant
medications (including vitamin B12 supplementation)
and survival status were collected at each visit. Overall
best response as evaluated by the physician was col-
lected at the final visit. The following solicited toxicities
were collected as maximum toxicity grades (none,
Grade 1/2, Grade 3/4) at each visit: neutropenia, febrile
neutropenia, mucositis, stomatitis, pharyngitis, fatigue,
asthenia, nausea, vomiting, diarrhea, and rash/desqua-
mation. An electronic data capture system was used to
collect these data. In addition, patients were asked to
document folic acid intake in patient diaries and to
complete the EQ-5D questionnaire [18] at each visit.
The questionnaire comprises 5 dimensions of health
(mobility, self-care, usual activities, pain/discomfort,
anxiety/depression). Each dimension comprises three
levels (some, moderate, extreme problems, rated from 1-
3). An overall EQ-5D index was calculated [19], with an
index of 1.0 representing full health. In addition,
patients evaluated their current health state on a visual
analogue scale (EQ-Visual Analogue Scale [VAS]; 0 =
worst, 100 = best imaginable health state).
Statistics
Approximately 580 patients were planned to be
observed. Assuming a 5% drop-out rate, this sample size
would allow the 95% confidence interval (CI) for the
proportion of patients showing a “KI benefit response”
to range between 3.6% (for an observed proportion of
4.9%) and 8.4% (for an observed proportion of 50%).
Data analyses were exploratory and performed using
SAS software (Statistical Analysis System Release 9.2,
SAS Institute). All eligible patients were included in the
primary analysis of KI benefit response. Those patients
who discontinued prior to the end of the second treat-
ment cycle or who had missing values concerning KI
were considered as non-responders in terms of KI bene-
fit response in the primary analysis (worst case sce-
nario). In a second, supporti v ea p p r o a c h ,t h ea n a l y s i s
was based on all patients who had non-missing data for
KI at baseline and after 2 cycles of treatment. For both
proportion estimates, 95% CIs based on the F distribu-
tion method were provided [20].
Factors potentially associated with achieving a KI ben-
efit response were investigated using logistic regression
analysis (univariate and multivariable modeling
approaches).
Changes from baseline in EQ-5D index and EQ-VAS
scores were explored using two-sided t-tests or sign-
tests in case of failed normality assumptions. EQ-5D
individual domains, disease control (defined as best
response of complete response, partial response or
stable disease as evaluated by physician), body weight,
concomitant medications and toxicities were analyzed
by descriptive statistics. Reasons for discontinuation,
type of prior chemotherapy, and solicited toxicities were
presented by decreasing frequency. OS was measured
f r o mt h ed a t eo ft h ef i r s tp e m e t r e x e dd o s et ot h ed a t e
of death due to any cause. If survival status was
unknown at the final follow-up, OS time was censored
at the last contact date. The median OS time was esti-
mated using the product limit method [21]. The asso-
ciated 95% CI was based on the sign test [22]. Follow-
up time was quantified using the “reversed” Kaplan-
Meier method [23].
Results
Patient disposition
Of 542 NSCLC patients with any documentation avail-
able, 521 (96.1%) patients were eligible for analysis. One
patient was excluded because he had received no pre-
vious chemotherapy, 19 patients because they had
received more than 1 chemotherapy regimen prior to
study entry. One patient had been set up in the electro-
nic data capture system before any treatment decision
was made and was excluded because there was no
further documentation and no plan to start second-line
pemetrexed treatment. Of the 521 eligible patients with
baseline data, 516 (99.0%) received at least one dose of
pemetrexed (2 patients died before the first dose, 3
patients were lost to follow-up or had missing data). 471
patients (90.4%) completed at least 2 cycles of peme-
trexed treatment. 254 patients (48.8%) completed at
least 6, and 110 (21.1%) at least 9 treatment cycles. 25
patients (4.8%) continued pemetrexed after the end of
the observational period. A median of 5 treatment cycles
(range 1 to 9) were documented.
Of all patients treated (N = 516), 28.9% completed the
treatment schedule as planned by the physician. The
most frequent reasons for early discontinuation of
pemetrexed were disease progression (27.7%), followed
by death (14.3%), patient decision (14.1%), toxicity
(4.5%), other reasons (3.9%) and loss to follow-up (1.2%).
Patient characteristics
Table 1 presents the baseline characteristics for all eligi-
ble patients (N = 521). The majority of all patients
(73.5%) had Stage IV disease, 37.8% of patients had a
poor baseline KI of < 80%. Patients overall had a median
Schuette et al. BMC Cancer 2012, 12:14
http://www.biomedcentral.com/1471-2407/12/14
Page 3 of 12Table 1 Baseline characteristics, all patients
All patients (N = 521)
Age
Years, median (range) 66.3 (39-86)
≥ 70 years, n (%) 188 (36.1)
Gender, n (%) male 363 (69.7)
Origin, n (%) Caucasian 514 (98.7)
Weight, kg [mean (SD)] 74.9 (14.45)
Smoking status, n (%)
Current smoker 139 (26.7)
Ex-smoker 243 (46.6)
Never smoked 138 (26.5)
Missing data 1 ( 0.2)
Histology, n (%)
Non-squamous cell carcinoma 444 (85.2)
Squamous cell carcinoma
a 77 (14.8)
Disease stage at study entry, n (%)
Stage IIIa 35 ( 6.7)
Stage IIIb 103 (19.8)
Stage IV 383 (73.5)
All patients (N = 521)
Karnofsky Index (KI), n (%)
KI ≥ 80% 323 (62.0)
KI 70% 134 (25.7)
KI 60% 45 ( 8.6)
KI 50% 18 ( 3.5)
Missing data 1 ( 0.2)
Type of previous first-line chemotherapy
Platinum-based combinations, n (%) 450 (86.4)
Platinum-free combinations, n (%) 12 ( 2.3)
Single-agent, n (%) 59 (11.3)
Most frequent agents used (at least 10% of patients), n (%)
b
Carboplatin 327 (62.8)
Cisplatin 135 (25.9)
Vinorelbine 162 (31.1)
Gemcitabine 159 (30.5)
Paclitaxel 131 (25.1)
Duration of previous first-line chemotherapy, months [median (range)] 3.5 (0-32)
Time elapsed since previous first-line chemotherapy, months [median (range)] 3.9 (0-74)
Patients [n (%)] who started pemetrexed
Immediately after end of first-line treatment
c 82 (15.7)
Within 3 months after end of first-line treatment
d 132 (25.3)
More than 3 months after end of first-line treatment
e 302 (58.0)
Missing data 5 (1.0)
N = total number of patients, n = number of patients, SD standard deviation
a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma
b) Multiple nominations possible
c) First dose of pemetrexed given ≤ 28 days after the last dose of first-line therapy
d) First dose of pemetrexed dose given > 28 days but ≤ 3 months after the last dose of first-lintherapy
e) First dose of pemetrexed dose given > 3 months after the last dose of first-line therapy
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old. The elderly patients were similar to the overall popu-
lation in terms of baseline KI and histology (Table 2).
Regarding previous first-line chemotherapy, 86.4% of
all patients had received platinum-based combinations
(Table 1). These were carboplatin-based in approxi-
mately two thirds of the patients (overall use: carbopla-
tin 68.2%, cisplatin 25.9% of patients). Median duration
of prior chemotherapy was 3.5 months. The majority of
patients (58.0%) had stopped prior chemotherapy (last
dose) more than 3 months before the start of this study.
Dose administration
The median initial pemetrexed dose was 500 mg/m
2
(range 330 to 500 mg/m
2). Overall, 232 patients (49.3%)
had at least one dose delay, but only 33 patients (7.0%)
had a dose delay due to toxicity. Doses were mainly
delayed due to scheduling conflicts (35.0%). At least one
dose reduction during the study was documented for 25
(4.8%) patients. Of these patients, 10 (40.0%) received a
dose ≤ 75% of the previous dose and 1 patient (4%)
received a dose of ≤ 50% of the previous dose.
Physician-rated PS (KI)
In this study, 58.0% of patients (302 of 521 patients; 95%
CI 53.6%; 62.2%) achieved a “KI benefit response” after
the second treatment cycle; KI improvement by at least
10% was achieved in 20.3% of patients and 37.6% main-
tained a high KI of at least 80% (Table 3). Of note,
20.8% of patients with a poor baseline KI < 80% had
improved to a KI of at least 80% after the second treat-
ment cycle (41of 197 patients) (Figure 1). 15.8% of
patients with a high baseline KI (51 of 323 patients)
deteriorated to a KI below 80% after the second cycle,
24 patients had missing data after the second cycle. If
patients with missing data were excluded from the ana-
lysis, the KI benefit response rate was 64.1% (95% CI:
59.6%; 68.5%). After the sixth treatment cycle, 74.4% of
254 patients still on treatment showed KI benefit
response (95% CI 68.6%; 79.7%). Median KI remained
unchanged at 80% throughout the study.
Figure 2 summarizes the analysis of potential factors
associated with the KI benefit response after the second
treatment cycle (univariate logistic regression analyses).
There was a significant advantage with respect to
achieving KI benefit response after the second treatment
cycle for patients who had a KI of ≥ 80% at baseline (p
<0 . 0 0 1 )a n df o rp a t i e n t sw h oh a dr e c e i v e df i r s t - l i n e
combination treatment as when compared with those
who had received single-agent treatment (p =0 . 0 0 5 ) .
Time elapsed since first-line chemotherapy had no sig-
nificant impact on KI benefit response. Patients who
had experienced Grade 3/4 toxicities during the first 2
treatment cycles had significantly less chance of achiev-
ing KI benefit response (p < 0.001). These results of the
univariate models were supported by multivariable mod-
eling approaches which gave similar results (data not
shown).
Patient-rated HR-QoL (EQ-5D)
Approximately half of the patients returned completed
EQ-5D questionnaires and therefore were evaluable for
HR-QoL. Patients’ mean EQ-5D index at baseline was
0.66 (standard deviation [SD] 0.256; N = 231 patients
with data available). A small, statistically significant
improvement of this score was noted after the second
treatment cycle, that is after approximately 6 weeks of
treatment (mean increase 0.02, SD 0.214; N = 190
Table 2 Disease characteristics by age group
Age < 70 years (N = 333) n (%) Age ≥ 70 years (N = 188) n (%) All patients (N = 521) n (%)
Histology
Non-squamous cell carcinoma 283 (85.0) 161 (85.6) 444 (85.2)
Squamous cell carcinoma
a 50 (15.0) 27 (14.4) 77 (14.8)
Disease stage at study entry
Stage IIIa 18 ( 5.4) 17 ( 9.0) 35 ( 6.7)
Stage IIIb 65 (19.5) 38 (20.2) 103 (19.8)
Stage IV 250 (74.1) 133 (70.7) 383 (73.5)
Karnofsky Index (KI)
KI ≥ 80% 207 (62.2) 116 (61.7) 323 (62.0)
KI 70% 89 (26.7) 45 (23.9) 134 (25.7)
KI 60% 27 ( 8.1) 18 ( 9.6) 45 ( 8.6)
KI 50% 10 ( 3.0) 8 ( 4.3) 18 ( 3.5)
Missing data 0 ( 0.0) 1 ( 0.5) 1 ( 0.2)
N = total number of patients, n = number of patients
a) The study started in 2007, before the label change in April 2008 which restricted the use of pemetrexed to patients with non-squamous cell carcinoma
Schuette et al. BMC Cancer 2012, 12:14
http://www.biomedcentral.com/1471-2407/12/14
Page 5 of 12patients; p = 0.003). For those patients remaining on
study, the EQ-5D index continued to improve up to
treatment cycle 6 (mean increase 0.11, SD 0.228; N = 61
patients; p < 0.001). Figure 3 presents patients’ mean
EQ-5D ratings for the 5 individual EQ-5D domains at
baseline and after the second, fourth and sixth treatment
cycle. For the pain/discomfort and anxiety/depression
dimensions, improvements had started after the second
treatment cycle. Improvements in mobility and usual
activities became visible after the fourth cycle only.
Patient self-care worsened initially after the second
cycle, but then improved up to treatment cycle 6.
Patients’ self-ratings of overall health status on the
EQ-VAS gave consistent results. The mean baseline EQ-
VAS score was 59.3 (SD 17.80; N = 225 patients). There
was a small, statistically significant improvement after
the second cycle (mean increase 3.3, SD 12.58; N = 182
patients; p< 0.001). EQ-VAS ratings continued to
improve significantly up to treatment cycle 6 (mean
increase 12.8, SD 17.62; N = 60 patients; p< 0.001).
Table 3 KI benefit response after the second treatment cycle (worst case scenario)
KI benefit response
a All patients (N = 521) n (%) of patients [95% CI]
Responders overall 302 (58.0) [53.6; 62.2]
0% improvement of KI, but maintained ≥ 80% 151 (29.0)
10% improvement of KI 97 (18.6)
20% improvement of KI 7 ( 1.3)
30% improvement of KI 2 ( 0.4)
Worsening of KI, but still maintained ≥ 80% 45 ( 8.6)
Non-responders, overall 219 (42.0) [37.8; 46.4]
0% worsening of KI, but maintained < 80% 67 (12.9)
Deterioration of KI, developed KI < 80% 102 (19.6)
Missing data
b 50 ( 9.6)
CI confidence interval, KI Karnofsky Index, N = total number of patients, n = number of patients
a) Defined as improvement in KI of at least 10% (absolute) or maintenance/achievement of an absolute KI of at least 80%
b) Patients who discontinued prior to the end of the second treatment cycle or who had missing KI data were considered as non-responders (worst case
scenario)
Number of patients
100% 13 11  5 3  1
90% 4  49 29 4 2 2 1  2
80% 2 46 89  29 3  1  1 2
70% 1 35  49 23 8 4  3
60% 1 3 11 13  4 1  4
50% 1  11  52   2
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Figure 1 Shift table presenting the number of patients by baseline KI and KI after second treatment cycle with pemetrexed.K I=
Karnofsky Index
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The overall disease control rate, with disease control
defined as physician-evaluated best response of complete
or partial response or stable disease, was 60.3% (314
patients; 95% CI 55.9%; 64.5%). After a median follow-
up time of 13.8 months, the median survival time was
11.1 months (95% CI 9.5 months; 12.2 months). The 12-
month survival rate was 45.8% (95% CI 40.7%; 50.7%),
25.6% of patients were still at risk (i.e., still under fol-
low-up).
Solicited toxicities, weight control and blood transfusions
The analysis of toxicities which were collected by soli-
cited questioning included 516 patients who received at
least one dose of pemetrexed. Overall, any Grade 3/4
toxicities were reported for 23.8% of patients. Two
patients (0.4%) died due to toxicity during the first treat-
ment cycle. Grade 3/4 toxicities reported for these
patients included febrile neutropenia for one patient
(male, 65 years, KI 90%), and fatigue/asthenia, mucositis,
neutropenia, and stomatitis/pharyngitis for the second
patient (male, 69 years, KI 70%). Grade 3/4 toxicities
occurred most frequently during the initial cycle (11.0%
of patients), less frequently during cycles 2 to 4 (8.5%,
9.0%, and 9.3% of patients, respectively), and then
decreased sharply after the fourth cycle (< 5% for all
cycles after cycle 4).
Table 4 summarizes the frequency of these solicited
toxicities by maximum toxicity grade as evaluated by
the physicians, for all patients, by baseline KI status and
by age group. Grade 3/4 toxicities reported in more
than 2% of patients were fatigue/asthenia (15.9%), neu-
tropenia (8.7%) and nausea (3.1%). Grade 3/4 toxicity
rates were twice as high in patients with poor baseline
KI (< 80%) when compared to patients with a baseline
KI of ≥ 80% (34.7% vs. 17.4%; see Table 4). There was
no evidence that Grade 3/4 toxicity rates were higher in
elderly than in younger patients ( ≥ 70 vs. < 70 years).
Analysis of body weight showed that weight loss was
rare. Only 5.4% of all patients lost ≥ 10% of body weight
during the period of documentation. Red blood cell
(RBC) transfusions were required by 24.2% of patients at
some time during the study; 9.2% of patients received a
RBC transfusion at baseline, 3.9% and 5.5% of patients
received RBCs at the time of the first and second peme-
trexed treatment, respectively (Table 5). Platelet transfu-
sions were required by 3.5% of patients, colony-
stimulating factors were administered to 11.1% of
patients. 95.2% of patients received dexamethasone pro-
phylaxis (or other steroid s )a ts o m et i m ed u r i n gt h e
Figure 2 Odds ratios for patients’ characteristics potentially associated with KI benefit response after the second treatment cycle.C I=
confidence interval, KI = Karnofsky Index. Odds ratios derived from univariate regression analyses, including all eligible patients (N = 521).
Reference categories: KI at baseline = < 80%, prior first-line chemotherapy = single agent, time elapsed since prior chemotherapy = immediately,
Grade 3/4 toxicities = none. Time elapsed since prior chemotherapy: Immediately = first dose of pemetrexed given ≤ 28 days after the last dose
of first-line therapy. Within 3 months = first dose of pemetrexed given > 28 days but ≤ 3 months after the last dose of first-line therapy. Later
than 3 months: first dose of pemetrexed given > 3 months after the last dose of first-line therapy
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vitamin B12. Further, 83.5% of patients received antie-
metics, 74.3% received analgesics, and 12.7% received
antidiarrheals. Intake of at least one dose of folic acid
was documented by 98.3% out of 292 patients with diary
information available [24].
Discussion
Second-line treatment improves survival and is increas-
ingly used in patients with advanced NSCLC [2,5,25].
Prospective data evaluating patients’ overall health con-
dition during second-line treatment as reflected by PS
or HR-QoL are still rare, in particular for elderly
baseline
after 2 cycles
after 4 cycles
after 6 cycles
1.8
1.6
1.4
1.2
1.0
Mobility
SelfͲcare
Usualactivities Pain/discomfort
Anxiety/
depression
Higherratingsrepresent
poorerQoL.
Figure 3 EQ-5D health status profiles: mean ratings for each of the 5 dimensions of the EQ- 5D questionnaire over time. On the EQ-5D
questionnaire, the patient rates each of the 5 dimensions (mobility, self care, usual activities, pain/discomfort and anxiety/depression) as
associated with “some problems” (= 1), moderate problems (= 2), extreme problems (= 3). EQ- 5D = European Quality Of Life Five Dimensions
questionnaire, QoL = Quality Of Life, n = number of patients
Table 4 Solicited Grade 3/4 toxicities (physician evaluation) by baseline KI and age group
n (%) of patients with maximum Grade 3/4 toxicity
Toxicity All patients treated
(N = 516)
Baseline KI ≥ 80%
(N = 322)
Baseline KI < 80%
(N = 193)
Age < 70 years
(N = 329)
Age ≥ 70 years
(N = 187)
Any toxicity 123 (23.8) 56 (17.4) 67 (34.7) 87 (26.4) 36 ( 19.3)
Fatigue/asthenia 82 (15.9) 32 ( 9.9) 50 (25.9) 54 (16.4) 28 ( 15.0)
Neutropenia 45 ( 8.7) 21 ( 6.5) 24 (12.4) 30 ( 9.1) 15 ( 8.0)
Nausea 16 ( 3.1) 6 ( 1.9) 10 ( 5.2) 10 ( 3.0) 6 ( 3.2)
Febrile neutropenia 10 ( 1.9) 3 ( 0.9) 7 ( 3.6) 6 ( 1.8) 4 ( 2.1)
Rash/desquamation 7 ( 1.4) 6 ( 1.9) 1 ( 0.5) 4 ( 1.2) 3 ( 1.6)
Stomatitis/pharyngitis 7 ( 1.4) 3 ( 0.9) 4 ( 2.1) 3 ( 0.9) 4 ( 2.1)
Mucositis 5 ( 1.0) 1 ( 0.3) 4 ( 2.1) 3 ( 0.9) 2 ( 1.1)
Vomiting 5 ( 1.0) 2 ( 0.6) 3 ( 1.6) 4 ( 1.2) 1 ( 0.5)
Diarrhea 2 ( 0.4) 1 ( 0.3) 1 ( 0.5) 2 ( 0.6) 0 ( 0.0)
KI Karnofsky Index, N = total number of patients, n = number of patients
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Page 8 of 12patients or patients with poor PS as frequently treated in
routine clinical practice. Patients older than 70 years are
of special interest; even their first-line treatment is
under continuous debate [25,26] because multimorbidity
and a higher incidence of toxicities are assumed to
reduce their overall clinical treatment benefit.
sOur study demonstrates that the majority of patients
with Stage III/IV NSCLC in routine clinical practice can
maintain or improve physician-rated PS (KI) and patient-
rated HR-QoL (EQ-5D) during second-line treatment
with single-agent pemetrexed. Our population included
36% of elderly patients. The majority of all patients
(58.0%) achieved KI benefit response after the second
treatment cycle (with 90% of patients still on study), and
KI benefit response rates increased further during the
subsequent cycles. Without second-line treatment, PS
and HR-QoL would most likely have declined due to the
disease progression. Even with treatment, a decline in PS
and HR-QoL would be expected for patients with disease
progression or major toxicities. Correspondingly, patients
who had experienced no Grade 3/4 toxicities during the
first 2 cycles had a significant advantage with respect to
achieving KI benefit response. Patients with high baseline
KI also had a significant advantage with respect to
achieving KI benefit response, indicating that it is impor-
tant to optimize patients’ general condition before start-
ing second-line treatment.
Several studies have underlined the importance of
considering PS for clinical practice. Lilenbaum et al.
found high prevalences of poor PS (Eastern Cooperative
Oncology Group [ECOG] PS 2-4, corresponding to a KI
< 80%) in lung cancer patients of 34% when rated by
physicians and of 48% when rated by patients [10]. Blag-
den et al. showed that both patient-and physician-rated
PS scores reflected duration of survival and disease
stage; physician-rated scores were only marginally more
predictive of survival [8]. A recent study in more than
26,000 NSCLC patients has shown that PS is an inde-
pendent risk factor for patient OS [11].
No previous study has looked at changes in PS during
second-line treatment. Only one post-hoc analysis of
d a t af r o maf i r s t - l i n et r e a t m e n ts t u d yh a sb e e np u b -
lished by Sculier et al. [27]. In their study, 485 patients
received three cycles of triple-agent treatment with cis-
platin, gemcitabine and ifosfamide. 25% of patients who
had a poor baseline KI of 60% to 70% achieved clinical
improvement, defined as high KI of ≥ 80%. These find-
ings are consistent with the improvement rate of 20.8%
in patients with poor baseline KI we observed with sec-
ond-line pemetrexed treatment.
We additionally looked at patient-rated HR-QoL,
using the EQ-5D self-estimation instrument. The EQ-
5D was chosen because it is a simple, validated and
commonly used questionnaire which can be completed
within a short time [15]. The disease-specific, multidi-
mensional tools commonly used in lung cancer studies,
such as the Lung Cancer Symptom Scale (LCSS) used
b yH a n n ae ta l .[ 6 ]i nas t u d yw h i c hc o m p a r e ds e c o n d -
line treatment with pemetrexed versus docetaxel, were
too complex for use in a routine clinical practice setting.
The EQ-5D has been validated into 36 official languages
(http://www.euroqol.org), including the German lan-
guage [28]. We found that on average, baseline EQ-5D
ratings were at least maintained, consistent with the
physician-based KI ratings. Mean EQ-5D index and EQ-
VAS scores even showed small improvements after the
second treatment cycle, i.e., as early as 6-weeks after the
initiation of pemetrexed treatment. The EQ-5D instru-
ment has rarely been used in NSCLC patients so far.
Grutters et al. have recently applied the EQ-5D in
Table 5 Disease- or treatment related concomitant medication as reported by physicians
Cycle N Analgesics
n (%)
Antiemetics
n (%)
Antidiarrheals
n (%)
Dexa or similar
steroids n (%)
CSF n (%) Other
medications n
(%)
RBC
transfusions n
(%)
Platelet
transfusions n
(%)
Overall 521 387 (74.3) 435 (83.5) 66 (12.7) 496 (95.2) 58 (11.1) 292 (56.0) 126 (24.2) 18 ( 3.5)
Baseline 521 270 (51.8) 182 (34.9) 6 ( 1.2) 244 (46.8) 12 ( 2.3) 187 (35.9) 48 ( 9.2) 5 ( 1.0)
Cycle 1 516 265 (51.4) 270 (52.3) 7 ( 1.4) 452 (87.6) 5 ( 1.0) 196 (38.0) 20 ( 3.9) 2 ( 0.4)
Cycle 2 471 242 (51.4) 288 (61.1) 20 ( 4.2) 430 (91.3) 14 ( 3.0) 201 (42.7) 26 ( 5.5) 0 ( 0.0)
Cycle 3 421 226 (53.7) 260 (61.8) 16 ( 3.8) 391 (92.9) 14 ( 3.3) 186 (44.2) 29 ( 6.9) 4 ( 1.0)
Cycle 4 344 178 (51.7) 215 (62.5) 15 ( 4.4) 327 (95.1) 17 ( 4.9) 155 (45.1) 30 ( 8.7) 3 ( 0.9)
Cycle 5 278 142 (51.1) 179 (64.4) 8 ( 2.9) 268 (96.4) 11 ( 4.0) 137 (49.3) 14 ( 5.0) 1 ( 0.4)
Cycle 6 254 129 (50.8) 168 (66.1) 7 ( 2.8) 244 (96.1) 9 ( 3.5) 125 (49.2) 15 ( 5.9) 0 ( 0.0)
Cycle 7 150 93 (62.0) 87 (58.0) 4 ( 2.7) 143 (95.3) 4 ( 2.7) 96 (64.0) 7 ( 4.7) 0 ( 0.0)
Cycle 8 135 88 (65.2) 64 (47.4) 5 ( 3.7) 131 (97.0) 4 ( 3.0) 87 (64.4) 6 ( 4.4) 1 ( 0.7)
Cycle 9 110 75 (68.2) 52 (47.3) 2 ( 1.8) 105 (95.5) 1 ( 0.9) 77 (70.0) 4 ( 3.6) 0 (0.0)
Final 516 289 (56.0) 253 (49.0) 21 ( 4.1) 317 (61.4) 25 ( 4.8) 203 (39.3) 60 (11.6) 8 ( 1.6)
CSF colony stimulating factors, Dexa dexamethasone, N = number of patients per cycle, RBC red blood cells
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with severe adverse events (dyspnoea grade ≥ 3) during
treatment had statistically significantly lower EQ-5D
index scores than patients without severe adverse events
[29], indicating that the instrument is sensitive enough
to detect health status changes during chemotherapy.
In our study, second-line pemetrexed treatment was
well tolerated by most patients. Two of 516 patients
(0.4%) died due to drug-related toxicity. There were no
signs of cumulative toxicities. On the contrary, Grade 3/4
toxicity rates decreased after repeated treatment cycles.
Patients in our study received a higher number of treat-
ment cycles than in the randomized phase III trial of sec-
ond-line pemetrexed treatment by Hanna et al. [6] which
allowed for treatment up to disease progression (median
5 vs. 4 cycles). In our study, 20% of patients received at
least 9 cycles and 5% continued pemetrexed treatment
after the end of study. Considering in addition that most
patients maintained or improved their PS and HR-QoL,
our data indicate that a high number of treatment cycles
do not impair patients’ quality of life.
The Grade 3/4 toxicity profile, recorded by solicited
questioning of specific non-hematologic toxicities, was
largely comparable to the unsolicited toxicity rates during
pemetrexed treatment published by Hanna et al. (e.g. feb-
rile neutropenia 1.9% vs. 1.9%, nausea 3.1% vs. 2.6%,
vomiting 1.5% vs. 1.0%, rash 1.4% vs. 0.8%). However, we
found higher rates of Grade 3/4 asthenia/fatigue (15.9%
vs. 5.3%) and Grade 3/4 neutropenia (8.7% vs. 5.3%).
Further, we found no evidence that Grade 3/4 toxicity
rates were higher in elderly than in younger patients.
These findings are well in line with a subgroup analysis
of toxicities in the Hanna study, performed by Weiss et
al., which also did not find any significant difference in
toxicities between older and younger patients ( ≥ 70 vs.
< 70 years) [30]. A previous metaanalysis of 3 studies on
pemetrexed first-line treatment in 764 NSCLC patients
also concluded that pemetrexed or pemetrexed-based
combinations produced similar treatment effects in
older and younger patients ( ≥ 65 and < 65 years) and
appeared to be well tolerated in the elderly population
[31]. Thus, it cannot be stated in general that treatment
toxicity is higher in elderly patients; this may depend on
the type of treatment used. A recent retrospective study
by Chrischilles et al. evaluated chemotherapy use and
adverse events during treatment of advanced NSCLC in
routine clinical practice and concluded that toxicity was
increased in elderly patients, but his study mainly looked
at first-line treatment with platinum-based combinations
[32]. One additional result of this US study was that
physicians used carboplatin-based combinations more
frequently than cisplatin-based combinations (65.3% vs.
10.4%). Our German and Austrian data were fully con-
sistent with these findings: Physicians used carboplatin-
based combinations as first-line treatment in approxi-
mately two thirds of patients (carboplatin 62.8%, cispla-
tin 25.9%). Administration of carboplatin is more
convenient and less emetogenic than cisplatin [33], and
carboplatin has been associated with less toxicity [34].
This may explain why the latter is preferred in routine
clinical practice.
Our study has limitations. First, the non-interventional
design to observe patients in routine clinical practice
prohibits any definite conclusion on the efficacy of sec-
ond-line pemetrexed treatment. In particular, tumor
response data are of limited value and cannot be com-
pared to clinical trial data because physicians may not
have performed standard radiologic assessments or clas-
sified response in accordance with the standard response
evaluation criteria in solid tumors (RECIST). Second,
our toxicity data cannot be directly compared with toxi-
city data from clinical trials, because the collection of
toxicities differed substantially: only a few solicited toxi-
cities were specifically asked for via tick-boxes; no com-
plete lists of Common Terminology Criteria for Adverse
Events (CTC-AE) were handed out to the investigators.
Patients may also have reported e.g. fatigue more fre-
quently due to the solicited questioning for specific toxi-
cities. The validity of these data may therefore be
questioned, although the majority of toxicity results
were in line with previous clinical studies of pemetrexed
[6]. Further, we did not differentiate between in-and
outpatient treatment although it can be assumed that
the majority of patients received the 10-minute infusion
either in outpatient practice or in the ambulance of the
hospital. Finally, only half of the patients returned com-
pleted EQ-5D questionnaires. The internal validity of
our QoL data may therefore be compromised because
the missing data may be informative and not at random.
The major strength of our study is that we looked at
second-line treatment in a large sample of patients as
routinely treated in clinical practice where there is a
particular lack of data [6]. Clinical trials in NSCLC
patients are often criticized for rarely enrolling elderly
patients or patients with poor PS. In the randomized
phase III trial by Hanna et al., 15.1% of patients in the
pemetrexed arm were ≥ 70 years old, and 10.6% of
patients had a poor baseline ECOG-PS of 2 [6,30]. In
our study, 36.1% of patients were ≥ 70 years of age, and
37.8% of patients had a poor baseline KI of < 80%.
Despite the higher proportions of elderly and poor-per-
formance patients in our study, overall disease control
rates with pemetrexed were comparable to those found
by Hanna et al. (60.3% vs. 54.9%).
Conclusions
In this large non-interventional study of second-line
pemetrexed treatment in patients with Stage III/IV
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Page 10 of 12NSCLC, including 36% elderly ( ≥ 70 years) patients,
physician-rated PS (KI) and patient-rated HR-QoL (EQ-
5D) were maintained or improved in the majority of
patients. Both, physician-rated PS and patient-rated HR-
QoL assessments should, perhaps, be given more weight
than minor radiologic changes in guiding treatment
decisions and evaluating the effectiveness of second-line
therapy. Patients with high baseline PS also had a signif-
icant advantage, showing that it is important to optimize
the patients’ general condition before starting treatment.
Treatment was well-tolerated by the majority of patients
and there were no signs of cumulative toxicities.
Patients received a higher number of treatment cycles
than in clinical trials of second-line pemetrexed treat-
ment; considering that most patients maintained or
improved their PS and HR-QoL, our data indicate that a
high number of treatment cycles do not impair patients’
quality of life. Grade 3/4 toxicity rates were higher in
patients with poor baseline PS, but not in elderly versus
younger patients, indicating that elderly patients can be
considered for second-line treatment with pemetrexed if
they have a high PS of ≥ 80.
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